menu search

Kronos bio presents positive preliminary data from phase 1 dose escalation portion of phase 1/2 kb-0742 study at aacr-nci-eortc

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manage...

October 13, 2023, 4:30 pm

Caribou biosciences: positive cb-010 data leads to first half 2024 catalyst

Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 ...

July 17, 2023, 5:11 am

Theratechnologies to present preliminary safety and efficacy data from phase 1 trial of sudocetaxel zendusortide in heavily pretreated cancer patients at asco 2023

MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharma...

May 25, 2023, 5:31 pm

Olema oncology announces op-1250 demonstrates attractive combinability with cdk 4/6 inhibitor palbociclib in phase 1b dose escalation study

OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- breast cancer, with no dose-limiting toxicities, and no observed...

December 7, 2022, 8:37 pm

Nuvectis pharma, inc. reports third quarter 2022 financial results and business highlights

The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansio...

November 8, 2022, 1:00 pm


Search within

Pages Search Results: